In the first clinical trial of its kind, Danish researchers investigated the efficacy of a combination treatment of ruxolitinib and low-dose pegylated interferon-α2 (PEG-INF α2) in patients with polycythemia vera and myelofibrosis, according to a study published in Haematologica.
In the first clinical trial of its kind, Danish researchers investigated the efficacy of a combination treatment of ruxolitinib and low-dose pegylated interferon-α2 (PEG-INF α2) in patients with polycythemia vera (PV) and myelofibrosis (MF), according to a study published in Haematologica.
PEG-INF α2 normalizes blood cell counts and may prevent disease-related complications in patients with PV and MF, while ruxolitinib may increase the efficacy and tolerability of PEG-INF α2, according to the authors.
They hypothesized “combination treatment may also have a synergistic effect on the malignant clone, and reduced dosage of both drugs may lead to fewer side effects compared with monotherapies.”
The multicenter, open-label, single arm phase 2 study included 32 patients with PV and took place over 2 years. Ten patients with PV (31%) achieved remission and 3 (9%) achieved complete remission. The trial also included 18 patients with MF; 8 (44%) achieved remission while 5 (28%) achieved complete remission. Forty-six of the patients included were previously intolerant or refractory to PEG-INF α2.
Researchers determined the treatment’s efficacy “based on hematological parameters, quality of life measurements, and Janus kinase-2 (JAK2) V617F allele burden.”
The study yielded the following results:
Overall, the “combination treatment improved cell counts, reduced bone marrow cellularity and fibrosis, decreased JAK2 V617F burden, and reduced symptom burden with acceptable toxicity in several patients with PV or MF,” the researchers said.
In addition, authors observed a statistically significant reduction in MPN-SAF total symptom score (TSS) from baseline to most time points, excluding at 1 and 2 years. Different items of the TSS were significantly reduced “at more than half of the time points, compared with baseline: early satiety (P <.05), night sweats (P <.01), itching (P <.01), and weight loss (P <.001).” There were no significant differences in TSS change between patients with MF and those with PV.
Although the dropout rate of the study was 16%, researchers found it comparable with rates in previous studies of PEG-INF α2.
Reference
Sørensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study [published online December 26, 2019]. Haematologica. doi: 10.3324/haematol.2019.235648.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More